JPH0343248B2 - - Google Patents
Info
- Publication number
- JPH0343248B2 JPH0343248B2 JP8083782A JP8083782A JPH0343248B2 JP H0343248 B2 JPH0343248 B2 JP H0343248B2 JP 8083782 A JP8083782 A JP 8083782A JP 8083782 A JP8083782 A JP 8083782A JP H0343248 B2 JPH0343248 B2 JP H0343248B2
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- acid addition
- formula
- addition salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 11
- 206010027374 Mental impairment Diseases 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 description 14
- 238000011282 treatment Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 208000013403 hyperactivity Diseases 0.000 description 6
- 241000282412 Homo Species 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229960001344 methylphenidate Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
- 229960001252 methamphetamine Drugs 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960000761 pemoline Drugs 0.000 description 2
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010062119 Sympathomimetic effect Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26371781A | 1981-05-14 | 1981-05-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57203048A JPS57203048A (en) | 1982-12-13 |
| JPH0343248B2 true JPH0343248B2 (enrdf_load_stackoverflow) | 1991-07-01 |
Family
ID=23002963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8083782A Granted JPS57203048A (en) | 1981-05-14 | 1982-05-13 | Minimal brain dysfunction remedy |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS57203048A (enrdf_load_stackoverflow) |
| AU (1) | AU558410B2 (enrdf_load_stackoverflow) |
| IE (1) | IE55181B1 (enrdf_load_stackoverflow) |
| ZA (1) | ZA823321B (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06206817A (ja) * | 1983-08-16 | 1994-07-26 | Wellcome Found Ltd:The | 医薬組成物 |
| US5177111A (en) * | 1989-12-14 | 1993-01-05 | Hoechst-Roussel Pharmaceuticals Inc. | Alkylamino- and alkylamino alkyl diarylketones and pharmaceutical compositions thereof |
| US5006563A (en) * | 1989-12-14 | 1991-04-09 | Hoechst-Roussel Pharmaceuticals Inc. | Alkylamino- and alkylamino alkyl diarylketones |
-
1982
- 1982-05-13 AU AU83658/82A patent/AU558410B2/en not_active Expired
- 1982-05-13 ZA ZA823321A patent/ZA823321B/xx unknown
- 1982-05-13 IE IE114782A patent/IE55181B1/en not_active IP Right Cessation
- 1982-05-13 JP JP8083782A patent/JPS57203048A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57203048A (en) | 1982-12-13 |
| IE55181B1 (en) | 1990-06-20 |
| IE821147L (en) | 1982-11-14 |
| AU8365882A (en) | 1982-11-18 |
| AU558410B2 (en) | 1987-01-29 |
| ZA823321B (en) | 1983-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Horowitz et al. | Hypertensive responses induced by phenylpropanolamine in anorectic and decongestant preparations | |
| Biederman et al. | A Comparison of Once-Daily and Divided Doses of Modafinil in Children With Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Study | |
| US4435449A (en) | Treatment of minimal brain dysfunction (MBD) | |
| JPS6143112A (ja) | 精神性欲機能障害治療剤 | |
| JP2016138142A (ja) | 大うつ病を有する患者において減量療法を提供する方法 | |
| Guelfi et al. | Clinical safety and efficacy of tianeptine in 1,858 depressed patients treated in general practice | |
| McKay | Long-term use of diethylpropion in obesity | |
| Starkstein et al. | Apathy and depression following stroke | |
| JPS63243028A (ja) | 基本的うつ病を軽減するためのうつ病治療剤 | |
| Nugent et al. | Glucocorticoid toxicity: single contrasted with divided daily doses of prednisolone | |
| JPH03170475A (ja) | 抑うつ症治療剤 | |
| JPH0343248B2 (enrdf_load_stackoverflow) | ||
| US20190224208A1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| Ginsburg | Lomotil (diphenoxylate and atropine) intoxication | |
| Basser | Purgatives and periodic paralysis | |
| Ratcliffe | Methadone poisoning in a child | |
| JPH0251885B2 (enrdf_load_stackoverflow) | ||
| JPS584718A (ja) | 新規適応症に用うる医薬製剤 | |
| EP4164650A1 (en) | Rabeximod in the treatment of rheumatoid arthritis | |
| Garriott et al. | Death in the dental chair: three drug fatalities in dental patients | |
| Bhettay | Double-blind study of sulindac and aspirin in juvenile chronic arthritis | |
| Barrow et al. | The use of purified veratrum viride alkaloids in the treatment of essential hypertension | |
| Cardoe et al. | A double-blind crossover comparison of tolmetin sodium and phenylbutazone in the treatment of rheumatoid arthritis | |
| Farber | Fever, vomiting, and liver dysfunction with procainamide therapy | |
| Pavelka et al. | Experience with high doses of ibuprofen in the long-term treatment of rheumatoid arthritis |